{"disease":{"id":"cd55-deficient-ple-chaple-disease","name":"cd55 deficient ple chaple disease"},"drugs":{"marketed":[{"drug_id":"pozelimab-bbfg","indication_name":"CD55-deficient PLE (CHAPLE disease)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"VEOPOZ","generic_name":"POZELIMAB-BBFG","company_name":"REGENERON PHARMACEUTICALS","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Pozelimab-bbfg blocks C5 cleavage, preventing C5a and C5b formation and inhibiting terminal complement activation."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}